Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC)
Mack, P. C., Farneth, N., Mahaffey, C., Lara, P., Gandara, D. R.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Enhanced detection of EGFR mutations in plasma from non-small cell lung cancer (NSCLC) patients using Scorpion primers
Holland, W., Davies, A. M., Farneth, N. C., Gautschi, O., Lara, P. N., Gandara, D. R., Mack, P. C.
Published in Journal of clinical oncology (20.06.2007)
Published in Journal of clinical oncology (20.06.2007)
Get full text
Journal Article
Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003
Mack, P. C., Redman, M. W., Chansky, K., Williamson, S. K., Farneth, N., Lara, P. N., Le, Q., Gumerlock, P. H., Crowley, J. J., Gandara, D. R.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Proeasome inhibition with bortezomib (PS-341) in combination with docetaxel (Doc) in prostate cancer (CaP) cells and xenografts
Farneth, N. C., Holland, W. S., Kenosi, T., Kimura, T., Lara, P. N., Gandara, D. R., Gumerlock, P. H.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article